Rotavirus is the leading cause of severe acute gastroenteritis (AGE) in early childhood, globally causing Ͼ500 000 deaths and 2.4 million hospital admissions each year for children who are younger than 5 years. 1 To combat this disease burden, 2 live oral rotavirus vaccines, RotaTeq (pentavalent rotavirus vaccine [RV5; Merck Vaccines, Whitehouse Station, NJ]) and Rotarix (monovalent rotavirus vaccine [RV1; GlaxoSmithKline Biologicals, Rixensart, Belgium]), have been developed and shown to be highly efficacious against severe rotavirus disease, including hospitalization (85%-98%), in large clinical trials. 2, 3 Since the introduction of RV5, several studies have reported on its postlicensure use and impact in real-world settings. In the United States, RV5 was introduced in 2006; by 2008, with modest 1-dose coverage of 31% in children who were younger than 2 years, the onset and peak of the 2007-2008 rotavirus season were delayed by 15 and 8 weeks, respectively, and the proportion of fecal specimens that were positive for rotavirus was reduced by 69%. 4 This decline in rotavirus activity persisted into the 2008 -2009 season. 5 A single-center case-control study that was conducted in Houston, Texas, and used a control group that combined children who had rotavirus-negative AGE or acute respiratory infection yielded a 3-dose vaccine effectiveness (VE) of 88% (95% confidence interval [CI]: 68%-96%) against rotavirus-AGE that required hospitalization or emergency department (ED) visits. 6 A nationwide health insurance claimbased, postlicensure study that compared concurrent cohorts of children who received 3 doses of RV5 with those who received 3 doses of diphtheria-tetanus-acellular pertussis and no doses of RV5 provided a VE for preventing ED presentations and hospitalizations as a result of rotavirus and all-cause AGE of 100% (95% CI: 87%-100%) and 59% (95% CI: 47%-68%), respectively 7 ; however, the performance of RV5 seems to be setting dependent. A case-control study in Nicaragua, a high-burden, developing country where 1-dose RV5 coverage quickly reached 80%, 8 demonstrated a 3-dose effectiveness of just 46% (95% CI: 18%-64%) at preventing hospitalization or intravenous rehydration. 9 Early evidence from double-blind, randomized, multicenter, placebocontrolled phase III trials in other developing countries supports this concept, with efficacy of 3 doses of RV5 of 64% (95% CI: 40%-79%) and 51% (95% CI: 13%-73%) against severe rotavirus gastroenteritis in Africa and Asia, respectively. 10 The scope for rotavirus vaccines to prevent global diarrhearelated deaths in children was demonstrated in Mexico, where RV1 was introduced in February 2006, reaching 1-dose coverage of at least 74% for children who were aged Յ11 months by December 2007. 11 When comparing median values for 2003 to 2006 with 2008 data, the diarrhea-related mortality rate was reduced by 41% (95% CI: 36%-47%) for children who were aged Յ11 months and by 29% (95% CI: 17%-39%) for those who were aged between 12 and 23 months. 11 The primary aim of this study was to calculate the VE of RV5 at preventing hospitalization in the first annual birth cohort of eligible children in the high 3-dose coverage setting of Queensland, Australia.
METHODS
The state of Queensland, Australia, has a population of 4.4 million people and a current annual birth cohort of 63 000. 12 Rotavirus vaccine was added to the Australian universal, publicly funded immunization program for all infants who were born on or after May 1, 2007 , with children in a given state or territory offered a full course of either RV1 or RV5. 13 In Queensland, this program commenced on July 1, 2007, with RV5.
Hospital Admission Data
The Queensland Hospital Admitted Patient Data Collection (QHAPDC) collects admission data from all public and private hospitals in Queensland. 14 
Vaccination Status of Hospitalized Children
The Vaccine Information and Vaccine Administration System (VIVAS) is the vaccination register and management system that records all vaccines that are administered in Queensland. VIVAS records only vaccines that are administered; it is not a population-based register and does not have records for individuals who receive no vaccines. VIVAS vaccination data are provided to the national, population-based Australian Childhood Immunization Register (ACIR).
RV5 vaccination records for hospitalized children were extracted from VIVAS for the period of July 1, 2007, to December 31, 2008 . Rotavirus vaccinations were considered valid when administered Ն14 days before rotavirus hospitalization. For this project, children with RV5 vaccination records markedly outside standard practice (receipt of rotavirus vaccine at Յ4 weeks or Ն52 weeks of age or interval between doses of Յ7 days) were validated by telephone contact with the vaccine service provider.
Population Vaccine Coverage
ACIR captures immunization data from children who are younger than 7 years and enrolled in the Australian universal health insurance scheme, Medicare. This is essentially a complete population register with 99% of the annual national birth cohort registered with Medicare by 1 year of age. Children who are not enrolled in Medicare can be added to the ACIR via a supplementary number. 17 The National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases provided population rotavirus vaccine coverage proportions, including children who had received no vaccine doses, from the ACIR for children who were born between May 1, 2007, and April 30, 2008 . ACIR coverage figures for 3-dose, primarycourse vaccines are typically calculated by using the "third-dose assumption": if a child has a record of receiving dose 3 in a series, then they are assumed to have received doses 1 and 2 and therefore to be fully vaccinated for the primary course of that vaccine, even if there is no record for dose 1 or 2 having been administered. 18, 19 For this analysis, coverage data used were as reported and were not modified by using the third-dose assumption.
Data Linkage and VE
Data linkage was performed in Microsoft Excel (Microsoft Corp, Redmond, WA). Data from multiple instances of the same individual within VIVAS and QHAPDC were collapsed to a single record, and records in both data sets were linked by using a created key that consists of surname and date of birth. Linkage was validated by using the given name. Minor spelling and other variations in the given name field (involving 1-letter differences, addition of the second given name to the first given name field, or addition of a hyphen in first given names with 2 words) were manually reviewed and accepted as valid linkages when surname and date of birth matched.
VE was calculated by using the screening method, comparing the proportion of cases vaccinated and the proportion of the population vaccinated (PPV), 20 with exact 95% CIs for proportions 21, 22 :
A case was defined as any child who was born between May 1, 2007, and April 30, 2008 , and had a QHAPDC record of hospital admission with a rotavirus or nonrotavirus AGE ICD-10-AM code in any field. The minimum age of analysis for eligible children was 35 weeks to allow for 3-dose vaccine administration (latest age for third dose delivery: 33 weeks) 23 and development of a protective immune response (2 weeks). 2 This criterion may have excluded some children for whom 3 doses of RV5 were delivered early, but given the structure and timing of routine primary course vaccinations in Australia, this number is likely to be exceedingly small. For the purposes of VE calculation, the unit of comparison was the child rather than the hospital admission. This means that children who had multiple admissions for AGE during the study period were included in the analysis data set once. The VE for RV5 at preventing hospitalization was calculated for the period from January 1, 2008 (6 months after program commencement), to December 31, 2008 , in the first 12-month birth cohort of children eligible for publicly funded vaccination.
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RESULTS

Hospital Admission Data
We 24 This rise in testing may be attributable to increased awareness of the morbidity and mortality that are associated with gastroenteritis in the institu- tionalized elderly and modified laboratory testing behavior. 24 Regardless, the increase in testing was associated with a 52% and 23% reduction in proportion of tested specimens that were rotavirus positive in 2007 and 2008, respectively, coinciding with RV5 introduction. 24 As with all observational methods, bias and other issues need to be considered when interpreting our findings. 25 Because the screening method compares the proportion of 2 groups vaccinated rather than rates in different exposure categories, we presented only 3-dose VE. If a vaccine requires multiple doses and is effective, then the distribution of dose coverage in the population (noncases), compared with cases, will show that more children have complete rather than partial coverage. Because our 3-dose coverage was very high, VE values for at least 1 dose (any dose) or at least 2 doses were dominated by children who had received 3 doses, making VE estimates very similar to the 3-dose only VE (data not shown).
The PPV value used in VE calculations in this study was not the result of a limited sampling exercise, and the key data sets-ACIR and QHAPDCare routinely collected and population based. Queensland children's vaccination records are provided to ACIR from VIVAS, and the validity of ACIR data has been assessed previously. The most likely ACIR inaccuracy is for PPV to be underestimated, 17, 18 which would result in an underestimation of VE, meaning that our VE estimates may be conservative. We previously demonstrated that rotavirus coding for public hospital admissions is highly specific for rotavirus disease. Between 2001 and 2006, of 222 children who were younger than 5 years and had rotavirus-coded hospitalizations, 197 (98%) of 201 with rotavirus testing available were laboratory confirmed. 15 There was no systematic change in hospital coding in the period covered by this study. Given the narrow age range of the children in the effectiveness component of this analysis-a 12-month birth cohort-we did not 29 In effect, our findings also represent a population-wide vaccine probe study, suggesting that misclassification of hospitalizations as a result of rotavirus by using incorrect or less specific AGE codes is common.
Indirect vaccine effects are seen in older age groups with reductions in rates of rotavirus and nonrotavirus AGE admissions in unvaccinated children and adolescents. This coincides with immediate reductions in the proportion of laboratory tests that were positive for rotavirus in all age groups after RV5 introduction. 24 In our setting, a prompt decrease in rotavirus transmission is likely to have occurred after the very rapid 1-dose (89.6%) and 3-dose (73.1%) coverage seen in the first 12-month birth cohort. The timing of Queensland's rotavirus season may also have been of benefit, with at least 2 months of publicly funded vaccination occurring in 2007 before the traditional peak rotavirus month of September. 24 Similar to 7-valent proteinpolysaccharide conjugate pneumococcal vaccine, 30, 31 these indirect effects were unable to be calculated in infant efficacy studies, and additional documentation of such benefits in other populations is required.
CONCLUSIONS
There is now a small but increasing collection of studies that show postlicensure effectiveness or ecological changes in rotavirus activity after RV5 introduction. [4] [5] [6] [7] [8] 24, 32 Our findings confirm these and provide ecological evidence of reductions in hospitalization rates in older, unvaccinated children and adolescents for rotavirus and nonrotavirus AGE. Additional postimplementation research is required to identify means to improve 3-dose coverage and to understand better the effectiveness variations in the various settings where RV5 is currently used. 33 Our findings should encourage consideration of vaccine use in similar industrialized countries. 34 
